China vs Sur: The number of people with susceptibility test result for rifampicin
China
237,238
in 2021
Sur
67
in 2021
China rank
2nd
Sur rank
2nd
The number of people with susceptibility test result for rifampicin over time
- China
- Sur
How they compare
China currently reports 237,238 against 67 in Sur, a difference of 237,171.
That makes China's figure about 3,540.9 times Sur's.
Across all 5 years both countries report, China has been ahead every year.
China ranks 2nd and Sur ranks 2nd of 155 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 156,421 | 81.33 | 156,340 | China |
| 2020s | 242,912 | 66.5 | 242,846 | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, China or Sur?
- China, at 237,238 against 67 in Sur as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between China and Sur?
- 237,171, with China ahead.
- How many years of comparable data are there for China and Sur?
- 5 years are reported by both, from 2017 to 2021.
- How do China and Sur rank globally for the number of people with susceptibility test result for rifampicin?
- China ranks 2nd and Sur ranks 2nd of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.